机构地区:[1]武汉大学中南医院整形美容科,武汉430071
出 处:《中华医学美学美容杂志》2025年第2期131-137,共7页Chinese Journal of Medical Aesthetics and Cosmetology
基 金:湖北省自然科学基金(2024AFD274,2023AFB678)。
摘 要:目的探讨两种微聚焦超声设备联合A型肉毒毒素(BoNT-A)注射用于面部年轻化的疗效。方法回顾性纳入2023年4月至2024年4月武汉大学中南医院整形美容科60例接受面部年轻化治疗的女性患者,年龄28~70(41.3±7.9)岁。根据患者接受的治疗方法分为对照组(仅使用微聚焦超声治疗,n=30)和联合组(使用微聚焦超声联合BoNT-A注射治疗,n=30),再根据所使用的微聚焦超声设备细分为4组:Peninsula Microultra®(PM)治疗仪组(n=15)、Intelligent Ultrasound®(IU)治疗仪组(n=15)、PM治疗仪+BoNT-A注射组(n=15)、IU治疗仪+BoNT-A注射组(n=15)。比较不同组别患者治疗前、治疗后6个月面部皱纹严重程度评价量表(WSRS)评分、Merz美学量表(MAS)评分、面部全球美学改善评分(GAIS)改善度,记录患者治疗后不良反应发生率。结果治疗后6个月,联合组WSRS评分及MAS评分均低于对照组(均P<0.001),而PM治疗仪组和IU治疗仪组、PM治疗仪+BoNT-A注射组和IU治疗仪+BoNT-A注射组WSRS评分及MAS评分差异均无统计学意义(均P>0.05)。对照组与联合组患者自评GAIS改善度分别为56.7%(17/30)、80.0%(24/30),联合组优于对照组(P=0.015);对照组与联合组术者评价GAIS改善度分别为70.0%(21/30)、96.7%(29/30),联合组优于对照组(P=0.007);而PM治疗仪组和IU治疗仪组、PM治疗仪+BoNT-A注射组和IU治疗仪+BoNT-A注射组患者自评与术者评价的GAIS改善度差异均无统计学意义(均P>0.05)。所有患者均未出现水疱、结痂、紫癜、淤青、瘢痕、周围性面瘫、过敏、肌无力、吞咽困难、发音困难等严重不良反应。结论微聚焦超声技术联合BoNT-A注射用于面部年轻化的疗效优于单独使用聚焦超声,而两种微聚焦超声设备的疗效差异无统计学意义。Objective To investigate the efficacy of two types of micro-focused ultrasound devices combined with botulinum toxin type A(BoNT-A)injection for facial rejuvenation.Methods A retrospective study was conducted,including 60 female patients aged 28-70(41.3±7.9)years,who received facial rejuvenation treatment at the Department of Plastic and Reconstructive Surgery,Zhongnan Hospital of Wuhan University,from April 2023 to April 2024.Patients were divided into two groups based on the treatment method:the control group(received only micro-focused ultrasound treatment,n=30)and the combined group(received both micro-focused ultrasound and BoNT-A injection,n=30).Additionally,patients were further categorized into four subgroups based on the type of micro-focused ultrasound device used:Peninsula Microultra®(PM)device group(n=15),Intelligent Ultrasound®(IU)device group(n=15),PM device+BoNT-A injection group(n=15),and IU device+BoNT-A injection group(n=15).The severity of facial wrinkles was assessed using the wrinkle severity rating scale(WSRS),the Merz aesthetic scale(MAS),and the global aesthetic improvement scale(GAIS)at baseline and 6 months post-treatment.Adverse event rates were also recorded.Results At 6 months post-treatment,the combined group showed significantly lower WSRS and MAS scores than the control group(both P<0.001).No significant differences were found between the PM and IU device groups,or between the PM+BoNT-A and IU+BoNT-A groups regarding WSRS and MAS scores(all P>0.05).Self-reported GAIS improvement was 56.7%(17/30)for the control group and 80.0%(24/30)for the combined group,with the combined group showing superior results(P=0.015).The physician-assessed GAIS improvement was 70.0%(21/30)for the control group and 96.7%(29/30)for the combined group,again with the combined group showing superior results(P=0.007).No significant differences were found in self-reported or physician-assessed GAIS improvement between the PM and IU device groups,or between the PM+BoNT-A and IU+BoNT-A groups(all P>0.05).No se
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...